Editas Medicine PE Ratio 2015-2021 | EDIT

Current and historical p/e ratio for Editas Medicine (EDIT) from 2015 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Editas Medicine PE ratio as of October 26, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Editas Medicine PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-27 36.80 0.00
2021-06-30 56.64 $-2.55 0.00
2021-03-31 42.00 $-2.17 0.00
2020-12-31 70.11 $-2.00 0.00
2020-09-30 28.06 $-1.74 0.00
2020-06-30 29.58 $-2.52 0.00
2020-03-31 19.83 $-2.78 0.00
2019-12-31 29.61 $-2.69 0.00
2019-09-30 22.74 $-2.47 0.00
2019-06-30 24.74 $-2.13 0.00
2019-03-31 24.45 $-2.26 0.00
2018-12-31 22.75 $-2.33 0.00
2018-09-30 31.82 $-2.65 0.00
2018-06-30 35.83 $-2.97 0.00
2018-03-31 33.15 $-2.80 0.00
2017-12-31 30.73 $-2.98 0.00
2017-09-30 24.01 $-3.24 0.00
2017-06-30 16.78 $-3.19 0.00
2017-03-31 22.32 $-3.08 0.00
2016-12-31 16.23 $-3.03 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.587B $0.091B
Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86